MOTS-c in Australia: a mitochondrial-derived-peptide research guide

MOTS-c in Australia. MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) — encoded within the 12S rRNA region of the mitochondrial genome and one of the better-characterised members of the MDP class. It is referenced across mitochondrial-stress, metabolic and cellular-senescence research literature. This guide is a research-reference summary for Australian researchers; it makes no medical, therapeutic, anti-ageing, or human-use claim, and in particular no weight-loss claim.

What a mitochondrial-derived peptide is

Most cellular peptides are encoded in the nuclear genome. Mitochondrial-derived peptides are the exception — short peptides encoded within the mitochondrial genome itself. The class includes humanin and the SHLPs; MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c) is the member most-studied in metabolic and AMPK-pathway research. Understanding MOTS-c as genome-encoded rather than synthetic-by-design is what places it in a distinct research strand from the synthetic mitochondrial-targeting peptides such as SS-31.

AMPK-pathway and mitochondrial-stress research

MOTS-c was identified and characterised by Lee and colleagues (Cell Metabolism, 2015), who described the peptide, its mitochondrial origin, and its role in the folate–methionine (AICAR) pathway leading to AMP-activated protein kinase (AMPK) activation and metabolic-homeostasis research readouts. Later work by Reynolds and colleagues (Nature Communications, 2021) reported MOTS-c as an exercise-responsive, mitochondrially-encoded regulator that translocates to the nucleus to influence stress-adaptive and metabolic gene programmes in research models. These two studies anchor MOTS-c as a reference peptide for AMPK-pathway and mitochondrial-stress research — a research tool, not a treatment.

MOTS-c alongside NAD+ and SS-31

Within the longevity strand of the catalogue, MOTS-c is frequently referenced alongside NAD+ (a cofactor for sirtuin-pathway research) and SS-31 (a mitochondrial-membrane-targeting tetrapeptide). Researchers compare the three because they interrogate mitochondrial biology by different routes: MOTS-c through a genome-encoded AMPK-linked peptide, NAD+ through cofactor availability, and SS-31 through cardiolipin-binding membrane targeting. The parallels — and the metabolic-research overlap with the growth-hormone-secretagogue compounds — are why MOTS-c sits near the CJC-1295 GHRH research guide in the mesh.

Identity, purity and the COA moat

Every batch of MOTS-c supplied by Elite AU Peptides is independently HPLC-tested by Janoshik before it is listed. The measured purity is published on the MOTS-c product page and in the lab-reports library — real batch number, measured percentage, independently verifiable at janoshik.com. MOTS-c is stocked in 10mg, 20mg and 40mg lyophilised vials; nothing is listed without a certificate on file.

Reconstitution and handling for research use

MOTS-c ships as a lyophilised powder. Reconstitute with bacteriostatic water for laboratory handling — for example, a 10mg vial in 2mL yields a 5mg/mL working stock; adjust to the concentration your assay requires. Store the lyophilised powder at −20°C protected from light; once reconstituted, refrigerate at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles.

Compliance and research-use framing

MOTS-c is not TGA-approved and is not a therapeutic good. Elite AU Peptides supplies it strictly for in-vitro and laboratory research use only — not for human or animal consumption. We make no medical, therapeutic, anti-ageing, longevity-outcome, weight-loss, or human-use claim; the material above summarises the published mitochondrial-derived-peptide literature for reference only. Researchers should consult primary peer-reviewed sources for pathway data and protocol-specific reference values.